Peptron, Inc. (KOSDAQ:087010)
242,000
-3,000 (-1.22%)
Jun 10, 2026, 3:30 PM KST
Peptron Revenue
Peptron had revenue of 1.97B KRW in the quarter ending March 31, 2026, with 21.38% growth. This brings the company's revenue in the last twelve months to 5.98B, up 39.25% year-over-year. In the year 2025, Peptron had annual revenue of 5.63B with 78.76% growth.
Revenue (ttm)
5.98B
Revenue Growth
+39.25%
P/S Ratio
955.12
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.71T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.63B | 2.48B | 78.76% |
| Dec 31, 2024 | 3.15B | -189.71M | -5.68% |
| Dec 31, 2023 | 3.34B | -2.47B | -42.52% |
| Dec 31, 2022 | 5.81B | -810.52M | -12.24% |
| Dec 31, 2021 | 6.62B | 3.50B | 112.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Epis Holdings | 1.51T |
| SK Biopharmaceuticals | 790.25B |
| SK bioscience | 665.42B |
| PharmaResearch | 565.48B |
| Hugel | 451.93B |
| LigaChem Biosciences | 125.87B |
| HLB Co., Ltd. | 85.20B |
| OliX Pharmaceuticals | 17.26B |